Vamifeport hydrochloride is under clinical development by Vifor Pharma Management and currently in Phase II for Sickle Cell Disease. According to GlobalData, Phase II drugs for Sickle Cell Disease have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vamifeport hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vamifeport hydrochloride overview

Vamifeport (VIT-2763) is under development for the treatment of haemochromatosis, beta thalassemia. It is administered through oral route. The drug candidate acts by targeting ferroportin.

Vamifeport was under development for the treatment of sickle cell disease.

Vifor Pharma Management overview

Vifor Pharma Management, a subsidiary of CSL Ltd, focuses on the discovery, development, and marketing of prescription medicines and non-prescription drugs specializes in areas such as iron deficiency, nephrology, and cardio-renal therapies. The company is headquartered in Glattbrugg, Switzerland.

For a complete picture of Vamifeport hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.